Zacks Research lowered shares of Siemens Healthineers (OTCMKTS:SMMNY – Free Report) from a hold rating to a strong sell rating in a research note released on Thursday morning,Zacks reports.
Several other equities analysts have also issued reports on SMMNY. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Siemens Healthineers in a research report on Tuesday, August 18th. Citigroup reissued a “buy” rating on shares of Siemens Healthineers in a research report on Thursday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.
Check Out Our Latest Research Report on Siemens Healthineers
Siemens Healthineers Stock Performance
Siemens Healthineers Company Profile
Siemens Healthineers AG is a Germany-based medical technology company that develops and supplies products, services and digital solutions for healthcare providers. Its portfolio supports medical imaging, laboratory diagnostics, cancer treatment, minimally invasive procedures and related clinical workflows.
The company’s imaging business offers magnetic resonance imaging, computed tomography, molecular imaging, X-ray and ultrasound systems. Its diagnostics activities include laboratory testing, point-of-care testing and diagnostic IT solutions.
Further Reading
- Five stocks we like better than Siemens Healthineers
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Siemens Healthineers Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siemens Healthineers and related companies with MarketBeat.com's FREE daily email newsletter.
